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A B S T R A C T
Purpose
Febrile neutropenia commonly complicates cancer chemotherapy. Outpatient treatment
may reduce costs and improve patient comfort but risk progression of undetected
medical problems.
Patients and Methods
By using our validated algorithm, we identified medically stable inpatients admitted for febrile
neutropenia (neutrophils  500/L) after chemotherapy and randomly assigned them to continued
inpatient antibiotic therapy or early discharge to receive identical antibiotic treatment at home. Our
primary outcome was the occurrence of any serious medical complication, defined as evidence of
medical instability requiring urgent medical attention.
Results
We enrolled 117 patients with 121 febrile neutropenia episodes before study termination for poor
accrual. We excluded five episodes as ineligible and three because of inadequate documentation
of the study outcome. Treatment groups were clinically similar, but sociodemographic imbalances
occurred because of block randomization. The median presenting absolute neutrophil count was
100/L. Hematopoietic growth factors were used in 38% of episodes. The median neutropenia
duration was 4 days (range, 1 to 15 days). Five outpatients were readmitted to the hospital. Major
medical complications occurred in five episodes (8%) in the hospital arm and four (9%) in the
home arm (95% CI for the difference, 10% to 13%; P  .56). No study patient died.
Patient-reported quality of life was similar on both arms.
Conclusion
We found no evidence of adverse medical consequences from home care, despite a protocol
designed to detect evidence of clinical deterioration. These results should reassure clinicians who
elect to treat rigorously characterized low-risk patients with febrile neutropenia in suitable
outpatient settings with appropriate surveillance for unexpected clinical deterioration.
J Clin Oncol 29:3977-3983. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Febrile neutropenia remains the most common iat-
rogenic cause of emergency hospitalization of pa-
tients with cancer.1 Although neutropenia is usually
self-limited and often aggressively treated with he-
matopoietic growth factors, patients who develop
fever require prompt, sustained, broad-spectrum
antibiotic therapy.2 For nearly three decades, the
standard of care for febrile neutropenic patients was
hospitalization until both fever and neutropenia re-
solved.3 More recently, validated decision rules be-
came available to identify patients at low risk of
significant new medical problems, justifying less in-
tensive surveillance.4-6 As a result, outpatient ther-
apy has partially replaced inpatient therapy for
some low-risk patients in therapeutic trials7-12 or ad
hoc treatment plans developed to reduce costs and
increase patient comfort.13-17 Trials confirming the
equivalence of intravenous monotherapy18 and oral
antibiotic combinations19,20 to traditional intrave-
nous combination therapy have simplified antibi-
otic treatment. However, outpatient management
reduces medical observation, potentially delaying
detection and treatment of medical problems, al-
though inpatient care may introduce risks that
outpatient care may avoid. Therefore, making
outpatient management of febrile neutropenia an
accepted standard requires high-level evidence
that it does not worsen medical outcomes.21,22
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 29  NUMBER 30  OCTOBER 20 2011
© 2011 by American Society of Clinical Oncology 3977
Prior trials comparing inpatient and outpatient management11,23-26 had
insufficient power to detect harm to patients and also had incon-
sistent methodology.27 In addition, the quality of life (QOL) and
economic consequences of outpatient treatment have been inade-
quately documented.28 Therefore, we performed a multicenter ran-
domized trial comparing early discharge with continued inpatient
care for low-risk patients with cancer who had febrile neutropenia.
PATIENTS AND METHODS
Eligibility
Adult outpatients at participating sites with postchemotherapy fever
( 100.5°F at presentation or by patient measurement at home) and neutro-
penia (absolute neutrophil count [ANC] less than 500/L) that persisted after
at least 24-hour inpatient observation were evaluated by the risk assessment
criteria of Talcott et al.4-6 Briefly, patients are at low risk if they are outpatients
at presentation; exhibit no indication for hospitalization other than fever and
neutropenia, such as systemic hypotension, altered mental status, respiratory
failure, or inadequate oral fluid intake during 24-hour observation; and have
adequately controlled cancer. For leukemia patients, cancer control is defined
as bone marrow–proven complete remission, and for patients without leuke-
mia, no evidence of disease progression after either the initial chemotherapy
regimen or at least two cycles of a subsequent regimen. Required diagnostic
tests included a chest radiograph without evidence of infectious pneumonitis
and blood cultures without pathogenic growth at enrollment. Exclusions
included AIDS-associated malignancy, neutropenia arising more than 21 days
after chemotherapy, and intensive chemotherapy requiring bone marrow or
peripheral stem-cell support. Nonmedical criteria for home care included the
ability to use available emergency medical assistance (but not a 24-hour care-
giver), residence within 2 hours by surface transportation to a hospital experi-
enced in emergency care of patients with cancer, permission of the patient’s
treating physician, and documented informed consent. Study sites included
Cancer and Leukemia Group B (CALGB) members from 1994 to 1999 and
three Boston area hospitals (Massachusetts General Hospital, Brigham and
Women’s Hospital, and the Lahey Clinic) during the final year of the study.
Each site identified a designated commercial home care provider who agreed
to provide protocol care for patients without out-of-pocket charges.
Random Assignment
Random assignments were computer-generated by using blocks and
stratified by use of colony-stimulating factors (CSFs), participating institution,
and whether random assignment occurred on weekends, holidays, or after
hours, for which sequenced sealed envelopes were used.
Treatment Program
Patients randomly assigned to home treatment were discharged when
home antibiotics became available. All patients were required to continue the
antibiotic regimen in use at the time of enrollment. The treating physician
could make subsequent antibiotic changes, but changes intended solely to
simplify the delivery of antibiotics at home were not permitted. Suggested
broad-spectrum antibiotic regimens for patients without penicillin allergy
included a semisynthetic penicillin and aminoglycoside combination or cefta-
zidime alone; for penicillin- and cephalosporin-allergic patients imipenem
alone or an aztreonam-containing regimen was suggested. However, other
regimens were evaluated at the investigators’ request. Additional antibiotic
agents indicated by clinical circumstances, including agents to increase Gram-
positive coverage,23 were at the discretion of the treating physician.
Use of CSF, a stratification factor, was optional. To reduce nephrotoxic-
ity observed in prior outpatient trials,7,8 oral fluid intake of at least 2 L daily was
strongly encouraged. Required laboratory studies included daily CBCs with
differential WBC counts; serum creatinine levels twice weekly, every other day
for patients receiving an aminoglycoside, and daily for patients receiving both
an aminoglycoside and vancomycin; and blood cultures daily for recurrent
fever and every other day for continuing fever. Aminoglycoside and vancomy-
cin peak and trough levels documented acceptable levels after dosing changes
and at least weekly. All patients received continued broad-spectrum antibiotic
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Fig 1. CONSORT diagram. (*) The study
design did not collect these data, in part
because the number of patients reviewed
varied according to the screening ap-
proach. At the Boston sites, we screened
approximately 10 patients for each eligible
patient. (†) We did not keep the data. In
Boston, the average acceptance rate (1-
refusal rate) was approximately 30%, in-
creasing from 15% in the first year of the
study to 45% in the final year, when the
concept of discharge home was more
familiar.
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therapy until granulocytopenia had resolved (neutrophils and band forms
 500/L) and patients were afebrile.
Follow-Up Care
Home treatment was supervised by the patient’s treating physician, with
additional assistance available from the research team. Patients at home were
required to measure their temperature and, by using an automated device,
measure their blood pressure at least four times daily. They were examined
daily by a home care nurse who used a written protocol and who was instructed
to contact the primary physician if abnormal findings occurred. In addition, a
physician examined each home care patient 2 to 4 days after discharge, at least
weekly thereafter, and whenever the patient, the home care nurse, or any
physician felt that the patient’s condition had significantly worsened. Outpa-
tients were readmitted to the hospital whenever a physician felt the patient’s
condition warranted it, the patient requested it, or it proved infeasible to
administer the prescribed antibiotic regimen at home. Specific medical events
also mandated readmission, including pathogenic growth in a blood culture
drawn 24 hours or more after the initiation of antibiotics, initiation of ampho-
tericin or empirical antiviral therapy, or a serious medical complication (see
Primary End Point). If readmitted, patients remained as inpatients until the
episode had resolved. Study observation continued until resolution of neutro-
penia, discontinuation of antibiotics, and resolution of any new medical prob-
lems. In most cases, antibiotics were discontinued when resolution of
neutropenia was documented, but the treating physician could order addi-
tional treatment or observation.
Primary End Point
Because death, the definitive failure outcome, is rare in low-risk febrile
neutropenia, requiring prohibitively large trials, the primary study outcome
was the occurrence of any medical complication during the study period,
broadly defined as any medical event requiring urgent diagnostic or therapeu-
tic intervention. Predefined complications included systemic hypotension
(systolic blood pressure  90 mmHg), respiratory failure (partial pressure of
oxygen [PO2]  60 torr, adjusted for hyperventilation), altered mental status,
congestive heart failure documented by chest radiograph, serious bleeding
(three or more unit transfusions within 24 hours), and transfer to an intensive
care unit. Two physicians determined whether a major medical complication
had occurred via blinded review of a clinical summary form, which docu-
mented the most severe medical events, extreme laboratory values, and any
radiographic abnormalities during the episode. Before review, the principal
investigator (J.A.T.) ensured that the form contained all essential medical
information but no reference to the treatment site. If disagreement arose, a
third reviewer made the final determination.
QOL was measured by using self-reported questionnaires completed
immediately after study enrollment and after discharge from the study. Instru-
ments included the European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30)29; the General
Well-Being Schedule (GWS),30 an assessment of global QOL validated in a
broad range of populations including patients with cancer31-33; the Technical
Quality, Communication, Interpersonal Care and Outcomes subscales of the
Consumer Satisfaction Survey of the Group Health Association of America,34
a measure of patient satisfaction with medical care; and a study-specific mea-
sure developed in a pilot study to assess the effect of treatment site, including
relationships with family and physicians and their sense of personal safety. In
addition, we assessed direct and indirect medical costs, including out-of-
pocket costs to patients and informal caregivers, and, for the latter, time lost,
reported in the accompanying article by Hendricks et al.35 Data management
was a collaborative project of the Center for Outcomes Research at the Massa-
chusetts General Hospital Cancer Center, the CALGB Statistical Center, and
the Quality Assurance Office for Clinical Trials at the Dana-Farber Can-
cer Institute.
Statistical Analysis
The primary study outcome was the frequency of medical complications.
The study was initially designed to detect a clinically significant increase from
4% of inpatient episodes in which at least one medical complication occurred
to an 8% outpatient complication rate. However, because comfort with out-
patient management of febrile neutropenia increased over time, we revised our
goal to a 6% increase, producing a goal of 224 episodes per arm assuming 80%
power, one-sided  of .05, and a 5% ineligibility rate. We constructed an
unconditional exact 95% CI for the difference in complication rates between
arms inverting two one-sided tests that were based on the standardized score
statistic, each at the 0.0025 significance level (StatXact 6.0, Cytel Software,
Cambridge, MA). We assumed that home antibiotic therapy would improve
QOL and decrease costs, making home care the preferred option unless it
increased medical risk. Therefore, the study used a one-sided statistical test of








PNo. % No. % No. %
Episodes 66 47 113
Age, years .55
Median 47 47 47
Range 20-81 25-74 20-81
Sex .34
Female 33 50 28 60 61 54
Male 33 50 19 40 52 46
Race/ethnicity .03
White, non-Hispanic 60 91 34 72 94 83
African American 4 6 9 19 13 12
Hispanic, Asian, American
Indian, other 2 3 4 8 6 5
Marital status .75
Single 13 21 8 17 21 19
Married 37 60 31 67 68 63
Separated, divorced,
widowed 12 19 7 15 19 18
Unknown 4 1 5
Education .06
High school or less 17 27 20 48 37 36
Attended college 16 26 5 12 21 20
Graduate work 29 47 17 40 46 44
Unknown 4 5 9
Living situation .46
Lives alone 8 14 3 7 11 11
Lives with family/partner 44 77 33 79 77 78
Lives with others 5 9 6 14 11 11
Unknown 9 5 14
Medical insurance .05
Insured 50 88 29 67 79 79
Disability/Medicaid 4 7 7 16 11 11
Uninsured/self-pay 3 5 7 16 10 10




administration 40 61 17 38 57 51
Clerical/sales/skilled labor/
service 16 24 14 31 30 27
Machinery
operator/laborer/
farmer/other 0 0 5 11 5 5
Not reported 10 15 9 20 19 17




student 34 52 16 35 50 45
Unemployed, retired 21 32 14 30 35 31
Disabled 11 17 16 35 27 24
Unknown 0 1 1
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whether outpatient care increased complications compared with hospital care.
Episodes of febrile neutropenia resolve without a detectable influence on the
risk of medical complications in subsequent episodes,8,9,29 particularly for
low-risk patients. Therefore, the unit of analysis for this study was an episode of
febrile neutropenia; patients could be enrolled for more than one episode. Our
assumption of independence was tested in the data analysis. However, because
a favorable study experience could encourage a patient to re-enroll, we re-
stricted QOL assessment to the first episode.
RESULTS
Between September 1994 and January 1999, 102 patient episodes were
registered, before closure by the CALGB for poor accrual. Between
August 15, 1999, and June 30, 2000, an additional 19 episodes were
registered when the trial briefly reopened in the Boston area before the
study was terminated. The process of enrolling patients was more
difficult than anticipated: eligible patients were more reluctant to
enroll than anticipated, particularly early in the study, and febrile
neutropenia occurred less often and recovery occurred earlier than
historical precedent, likely reflecting the increasing use of hematopoi-
etic growth factors. Enrollment was largely confined to five study sites:
Massachusetts General Hospital, the Dana-Farber Cancer Institute/
Brigham and Women’s Hospital, University of North Carolina Hos-
pitals, the Southeast Cancer Care Consortium, and the University of
Massachusetts at Worcester, although eight other sites contributed
at leastoneotherpatient.Asaresultof thesparseaccrualatmanysitesand
block randomization, imbalances between treatment arms occurred
in patient numbers and some sociodemographic characteristics.
Of the 121 episodes, we excluded five—three because consent
was withdrawn before treatment and two in which neutropenia had
resolved at enrollment. For three additional episodes, the primary
study end point, major medical complications, could not be deter-
mined because of incomplete clinical documentation (Fig 1). One
patient participated in three different episodes and another in
two episodes.
Table 2. Clinical Characteristics at Presentation
Characteristic
Hospital Care Early Discharge All Patients
PNo. % No. % No. %
Cancer diagnosis .61
Acute leukemia 6 9 7 15 13 12
Lymphoma 13 20 13 28 26 23
Breast cancer 16 24 13 28 29 26
Sarcoma 9 14 4 9 13 12
Lung cancer 6 9 3 6 9 8
Other 16 24 7 15 23 20
Fever (maximum inpatient in initial 24 hours), °F .90
Median 101.4 101.4 101.4
Range 98.6-106.0 98.8-104.3 98.8-104.3
WBC per microliter .34
Median 0.7 0.8 0.7
Range 0.1-8.1 0.1-32.0 0.1-32.0
ANC  103/L .13
Median 57 100 100
Range 0-980 0-600 0-980
Platelets  103/L .88
Median 89 97 91
Range 1-657 8-365 1-657
Hematocrit .41
Median 29.3 30.6 29.9
Range 9.4-46.8 8.1-42.1 8.1-46.8
Creatinine, mg/dL .35
Median 0.9 0.8 0.8
Range 0.4-2.0 0.5-1.9 0.4-2.0
Chest x-ray on admission .42
Normal 48 74 36 78 84 76
Stable/improved 11 17 4 9 15 14
Other 6 9 6 13 12 11
Unknown 1 1 2
No. of days since previous chemotherapy .89
Median 11 11 11
Range 1-18 2-21 1-21
Use of G-CSF 1.0
Yes 25 38 17 37 42 38
No 41 62 29 63 70 63
Unknown 0 1 1
Abbreviations: ANC, absolute neutrophil count; G-CSF, granulocyte colony-stimulating factor.
Talcott et al
3980 © 2011 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
We report the remaining 113 patient episodes (Table 1). The
median age, 47 years, was the same in both study arms. Home care
patients were more often African American and less likely to have
high-status jobs and private medical insurance or Medicare.
Among hospital arm patients, there was a trend toward more
full-time employment and greater educational attainment.
Clinical characteristics for the treatments groups were similar
(Table 2), including initial peak fever (median, 101.4°F), hematologic
values, serum creatinine, chest radiograph findings, and time since
chemotherapy. The ANC at presentation was low (median, 100/L).
and CSFs were used in 38% of episodes.
For patients in both arms, the median duration of fever was 3
days, duration of neutropenia was 4 days, and duration of the febrile
neutropenia episode was 4 days, consistent with their assessment as
low-risk patients, although episodes extended to 15 days (Table 3).
The most common antibiotic regimen was single-agent anti-
Pseudomonas monotherapy, usually ceftazidime (37%), or with an
anti-staphylococcal agent (an additional 16%) and was similar be-
tween study arms (data not shown). Subsequent antibiotic changes
were more frequent for hospitalized patients (24% v 9%; P  .04).
Patients receiving CSFs had shorter neutropenia (median, 3 v 4 days;
P  .001) but similar duration of fever and frequency of antibiotic
changes (data not shown).
Four outpatient episodes resulted in hospital readmission. Major
medical complications occurred in five episodes (8%) on the hospital
arm and four episodes (9%) in the home arm (exact 95% CI for
outpatient v hospital complication rate, 10% to 13%; P  .56). Eight
complications involved hypotension (systolic blood pressure  90
mmHg), which was transient. One episode also included progressive
pain from a perianal wound. One patient had a pulmonary embolus
the day after discharge from the study. No study patient died.
QOL Results
One hundred ten patients completed the on-study assessment,
and 105 patients completed the off-study assessment. The three repeat
enrollments were excluded from the QOL portion of the study.
Reported pain decreased for home care patients and slightly
increased for hospitalized patients (change, 13.1 v 2.72; P  .01).
The Role Function subscale of the EORTC QLQ C-30 increased less
for home care patients than for hospitalized patients (change, 0.58 v
0.78; P  .05), but Emotional Function scores increased for home care
patients while declining for hospitalized patients (change, 3.27 v
6.94; P  .04). No other QLQ-C30 subscale differences were evi-
dent. Similarly, few differences appeared in the instrument comparing
the inpatient and outpatient care experience. Home care patients
more readily endorsed the statement “It is hard for me to relax …
when I am disturbed… by activities of the hospital” after completing
treatment, although agreement for hospital patients declined (change,
0.41 v 0.15; P  .08). The pattern was reversed for the statement
“When out of the hospital I become worried about being able to reach
my doctor when I need him or her” (change, 0.22 v 0.23; P  .07).
No differences were noted in response to the Consumer Satisfaction or
General Well-Being instruments.
DISCUSSION
Outpatient treatment of febrile neutropenia is attractive because of
potential cost savings and improved patient comfort. However, the
decision to discharge patients from the hospital requires that clinicians
be confident that the reduced opportunity for medical surveillance of
outpatients will not increase their medical risk. This question lends
itself to empirical evaluation: inpatient treatment is standard, the






PNo. % No. % No. %
Duration of fever (admission for T  99.5°F for 24 hours)
Median 3 3 3 .94
Mean 3.2 3.4 3.3
Range 0-13 1-14 0-14
Duration of neutropenia (initial admission for ANC  500/L)
Median 4 4 4 .80
Mean 4.1 4.2 4.1
Range 1-10 1-15 1-15
Duration of fever and neutropenia (admission for T  99.5°F for 24 hours, ANC  500/L,
and resolution of all medical problems)
Median 4 4 4 .70
Mean 4.6 4.5 4.6
Range 2-13 1-15 1-15
Antibiotics changed after random assignment 16 24 4 9 20 18 .04
Hospital readmission — 4 9 —
Major medical complications
Hypotension 5 8 3 6 8 8
Other (anal pain) 1 1 1 2 2 2
Any major complication 5 8 4 9 9 8 .56
Abbreviations: ANC, absolute neutrophil count; T, temperature.
One-sided test.
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episode’s end is numerically defined (by an ANC  500/L), and
validated measures exist to identify low-risk patients.4-6 In this multi-
center trial, we randomly assigned rigorously identified low-risk pa-
tients with febrile neutropenia to either early discharge to home
antibiotic therapy or continued hospital care. By using a sensitive
indicator of medical instability (ie, the occurrence of even transient
medical complications), we found little evidence that home care in-
creased risk.
Prior studies documented few medical problems for patients
with low-risk febrile neutropenia when given protocol-specified out-
patient antibiotic treatment.7-10,13-16 Despite these broadly reassuring
results, rigorous assurance that discharging low-risk patients does not
compromise patient safety has been unavailable. The most common
end point in outpatient therapy trials has been “response to therapy,”
or prompt resolution of infection without antibiotic changes.27 Devel-
oped to compare empirical antibiotic regimens for febrile neutrope-
nia, that outcome is less directly relevant to the fundamental question
of the safety of home therapy than our main outcome, occurrence of
serious medical problems potentially averted by earlier detection and
treatment. As a result, “response to therapy” cannot address the more
fundamental question addressed here: Are occasionally reported cat-
astrophic outpatient events such as the apparently preventable death
from sepsis in the study of Malik et al23 anomalies equally likely in the
hospital, or are they insensitive indicators of usually less serious but
common adverse events attributable to outpatient treatment? Our
data support the former interpretation.
However, these encouraging results may depend on elements of
our treatment plan omitted by other outpatient treatment protocols.
We used a validated clinical decision rule to identify patients for our
study, as recommended.27 Two risk assessment decision rules for
febrile neutropenia have been validated: our own4,5 and the Risk Index
of the Multinational Association for Supportive Care in Cancer
(MASCC).6 That validated risk assessment measures exist does not
justify assessing risk by using ad hoc clinical judgment, imprecisely
defined criteria such as “brief anticipated duration of neutropenia,” or
broad and sometimes misleading indicators of risk, such as the diag-
nosis of leukemia or lymphoma. For example, Elting et al16 found that
all 121 of the 712 patients assigned to an outpatient treatment clinical
pathway who were subsequently readmitted to the hospital would
have been designated as high-risk by using the MASCC risk index.
Patients in this study did well despite putative high-risk characteristics,
such as leukemia or lymphoma diagnoses and neutropenia with neu-
trophils below 100/L. Safe discharge of patients with febrile neutro-
penia requires an adequate structure of clinical support, including
regular patient evaluation, which our protocol provided, to identify
evidence of clinical instability or other evidence that the initial assess-
ment of low risk has changed, meriting closer surveillance.
Despite our hypothesis that home care would improve patient
QOL, we found, at most, modest supporting evidence. This result,
surprising given that study patients were self-selected by their interest
in possible home treatment, may be due to unexpected challenges in
receiving home intravenous antibiotics; failure to identify a suitable,
sensitive measure of QOL; inadequate study power; or the brief course
of low-risk febrile neutropenia. Finally, voluntary participants in a trial
offering possible home care may have lower risk than unwilling pa-
tients discharged early.
Although limited by reduced power secondary to low accrual,
our study documents important constraints on the risk of outpatient
treatment, ranging from a 13% increase to a 10% decrease in the risk of
developing medical instability (in most cases transient hypotension).
It provides the most stringent evidence to date that rigorously charac-
terized low-risk patients are put at minimal medical risk if discharged
to home antibiotic therapy under daily clinical evaluation. Given the
increasing acceptance of outpatient management of febrile neutrope-
nia, our study may represent the last major effort to rigorously char-
acterize its risk. Our inability to find evidence of adverse medical
consequences from home care, despite an aggressive search for indi-
cators of clinical deterioration, should reassure patients and physi-
cians considering appropriately designed outpatient treatment for
low-risk febrile neutropenia.
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